Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from ABBV

Are Pfizer (PFE) and AbbVie (ABBV) Good Value Buys for August?

The pharma industry is poised to witness long-term growth with the introduction of generic medicines and growing demand for personalized and targeted treatments. Hence, fundamentally strong pharma stock AbbVie (ABBV) might be worth buying. However, it might not be the right time to invest in Pfizer (PFE). Keep reading.

StockNews.com

3 High-Paying Unusually Active Put Options to Sell for Extra Cash This Weekend

It’s the last day of the trading week, so investors are looking for extra spending money for the weekend ahead. Here are three unusually active put options to sell: high-paying and worthwhile long-term holds.

Barchart

Is AbbVie (ABBV) a Better Stock to Buy Than Pfizer (PFE)?

Due to the emergence of new technologies and the introduction of generic medicines, the pharma industry seems well-positioned to witness growth. While pharma stocks should benefit from the industry tailwinds, let us analyze whether AbbVie (ABBV) is a better buy than Pfizer (PFE).

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 July Pharma Picks for Profit

The pharma industry performs relatively well during downturns due to inelastic demand for its products and services. Therefore, fundamentally strong pharma stocks Novo Nordisk (NVO), AbbVie (ABBV), and Novartis (NVS) might be profitable buys. Read on.

StockNews.com

AbbVie (ABBV) vs. Pfizer (PFE) - Which Pharma Stock Comes out on Top?

With the growing prevalence of chronic conditions, an aging population, widespread adoption of digital technologies, and several R&D efforts, the pharmaceutical industry is poised for exponential growth and expansion. So, let’s compare leading pharma stocks AbbVie (ABBV) and Pfizer (PFE) to identify which is a better investment now. Keep reading….

StockNews.com

3 Dependable Dividend Stocks to Consider in the Second Half Of 2023

These 3 dividend stocks have uninterruptedly paid and raised their dividends for years. Further, these stocks have outperformed the broader markets, and Wall Street analysts have a favorable outlook on them.

Barchart

AbbVie (ABBV) and Catalyst Pharmaceuticals (CPRX): Analyzing Investment Potential

The pharmaceutical industry’s inelastic demand for its products helps it to weather economic downturns. With fears of an impending recession playing on the minds of investors, it could be wise to buy fundamentally strong pharmaceutical stock AbbVie (ABBV). On the other hand, given its mixed fundamentals and profitability, it could…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Best Retirement Stocks for Income Investors in the Golden Years

The best retirement stocks ideally have attractive dividends that can be sustained. This can lead to steady income and long-term value for retirees.

Kiplinger

AbbVie’s Call Action Suggests It Might Just Be a Buy

Barchart.com’s Unusual Options Activity on Wednesday had 18 AbbVie call options in the Top 100. Not everyone believes it’s an excellent time to buy ABBV stock. Yesterday’s options market says otherwise.

Barchart

2 Top Stocks That Should Be on Your Radar This Spring

Amidst the turmoil in the banking sector, high inflation, and the Fed’s restrictive monetary policy, the economy faces a threat of recession this year. However, fundamentally strong stocks AbbVie (ABBV) and Salesforce (CRM) might be worth adding to your watchlist. Read more.

StockNews.com

3 Stocks to Buy Now That Are Worth Every Penny

Over the past year, the central bank has raised interest rates eight times to control inflation, which is still well above its 2% goal. The recent collapse of the financial system further complicates the Fed’s efforts in its fight against stubborn inflation. Amid this, it could be wise to invest…

StockNews.com

3 Highly Rated Blue-Chip Stocks for Your Portfolio

Despite a drop in inflation, recent developments have been concerning. Moreover, the Fed is in a dilemma of stabilizing the banking industry or fighting inflation. With uncertainty looming over the stock market, high-quality blue-chip stocks Johnson & Johnson (JNJ), Coca-Cola (KO), and AbbVie (ABBV) could be solid additions to your…

StockNews.com

Want Passive Income? Buy These 4 Stocks

Powell's testimony to keep the interest rates higher if required has created chaos in the markets, with the U.S. jobs report looming large for the future of monetary policy. Given the volatile market backdrop, fundamentally sound dividend-paying stocks AbbVie (ABBV), Cisco Systems (CSCO), Westlake Chemical Partners (WLKP), and Spok Holdings…

StockNews.com

3 Large-Cap Stocks Ready for a Bull Run

The stock market is anticipated to remain volatile due to stubbornly high inflation and the Fed’s rate hikes. Large-cap stocks tend to be safer investments amid market uncertainties. So, fundamentally sound large-cap stocks, AbbVie (ABBV), The Coca-Cola Company (KO), and Oracle (ORCL), which look poised for a bull run, might…

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Safe Haven Stocks to Buy in a Bear Market

Amid the diminishing likelihood of a Fed pivot and recession odds soaring, a bear market could be expected anytime soon. Therefore, investors can scoop up quality stocks Walmart (WMT), AbbVie (ABBV), and CVS Health (CVS) now. Read on….

StockNews.com

The 3 Best Pharma Stocks to Buy for Big Gains in 2023

The pharma industry witnessed solid growth amid the pandemic. Moreover, with surging demand, rising investments in research and development, and increasing e-pharmacy channels, the industry is well-positioned for significant growth over the coming years. Therefore, investors could consider buying fundamentally sound pharma stocks Johnson & Johnson (JNJ), AbbVie (ABBV), and…

StockNews.com

3 High-Quality Stocks You'll Kick Yourself Later for Not Buying

Despite recent signs of moderation in inflation, the better-than-expected January jobs data could force the Fed to raise interest rates even further. This is expected to keep the stock market highly volatile in the near term. Given a volatile market backdrop, investing in high-quality stocks AbbVie (ABBV), Cintas (CTAS), and…

StockNews.com

3 Income Stocks to Buy Now if You're Starving for Cash

The Fed will likely keep raising interest rates to bring inflation down to its desired level. This is expected to keep the stock market and the economy under pressure this year. Amid the uncertainty, investors looking for passive income could add fundamentally strong dividend-paying stocks AbbVie (ABBV), Valero Energy (VLO),…

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

The 5 Best Stocks to Invest $1,000 in Right Now

Improving investors’ sentiments amid the cooling inflation and moderating interest rate increases helped the stock market to surge in recent weeks. Moreover, the IMF raised its world economy growth forecast. Given the rising optimism, AbbVie (ABBV), Vertex Pharmaceuticals (VRTX), Murphy (MUSA), MasterCraft Boat (MCFT), and PrimeEnergy Resources (PNRG) might be…

StockNews.com

These 3 Dividend Stocks Are Worth Investing In

While the better-than-expected GDP growth in the last quarter and declining inflationary pressures are raising optimism, macro uncertainties remain. With interest rate hikes expected to continue, recession possibilities cannot be ruled out. Therefore, fundamentally sound dividend-paying stocks, AbbVie (ABBV), Gilead Sciences (GILD), and Sisecam Resources (SIRE), could be worth investing…

StockNews.com

3 High-Quality Stocks to Buy Hand Over Fist These Days

Even after inflation showed signs of cooling, fears of a recession continue to linger on investors. Despite having a muddled outlook of the market ahead, many experts believe there is still room for optimism. Given this backdrop, fundamentally sound high-quality stocks AbbVie (ABBV), Cisco Systems (CSCO), and Hugo Boss (BOSSY)…

StockNews.com

3 Top Pharma Stocks to Buy for the Long Haul

Rising chronic diseases, an aging population, and surging healthcare spending should boost the pharmaceutical industry’s growth prospects. Moreover, the pharmaceutical industry usually holds up well during market downturns due to relatively inelastic demand for their products and services. Therefore, fundamentally sound pharma stocks Johnson & Johnson (JNJ), AbbVie (ABBV), and…

StockNews.com

3 Safe High-Dividend Stocks to Buy Right Now

While inflation pressures seem to be cooling, the Fed is expected to continue with its rate hikes, raising the chances of a recession this year. Hence, high-dividend stocks AbbVie (ABBV), Gilead Sciences (GILD), and Marine Products (MPX) might be solid buys for steady income amid current uncertainties. Keep reading.

StockNews.com

The #1 Pharma Stock to Buy in January 2023

While the stock market and the economy have been subdued by progressive interest-rate increases, AbbVie Inc. (ABBV) has not only reported a robust third quarter but also demonstrated its confidence in its long-term prospects by raising its quarterly dividend. Read on….

StockNews.com

3 Safe Dividend Stocks to Buy Today and Hold Forever

Amid diminishing inflationary pressures, rate hikes are expected to slow down. However, the Fed might continue with the rate hikes. As a recession looks imminent, we think fundamentally sound dividend stocks AbbVie (ABBV), Marine Products (MPX), and Bassett Furniture Industries (BSET) might be ideal buy-and-hold options to ensure a steady…

1 … 5 6 7 8

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

International Monetary Fund

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.